West Pharmaceutical Services Stock-Based Compensation 2010-2025 | WST
West Pharmaceutical Services annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- West Pharmaceutical Services stock-based compensation for the quarter ending March 31, 2025 was $1M, a 74% decline year-over-year.
- West Pharmaceutical Services stock-based compensation for the twelve months ending March 31, 2025 was $0.044B, a 33.99% decline year-over-year.
- West Pharmaceutical Services annual stock-based compensation for 2024 was $0.019B, a 19.74% decline from 2023.
- West Pharmaceutical Services annual stock-based compensation for 2023 was $0.023B, a 1.69% decline from 2022.
- West Pharmaceutical Services annual stock-based compensation for 2022 was $0.024B, a 36.8% decline from 2021.
West Pharmaceutical Services Annual Stock-Based Compensation
(Millions of US $) |
| 2024 |
$19 |
| 2023 |
$23 |
| 2022 |
$24 |
| 2021 |
$38 |
| 2020 |
$34 |
| 2019 |
$24 |
| 2018 |
$15 |
| 2017 |
$16 |
| 2016 |
$20 |
| 2015 |
$30 |
| 2014 |
$19 |
| 2013 |
$21 |
| 2012 |
$16 |
| 2011 |
$8 |
| 2010 |
$8 |
| 2009 |
$8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$15.565B |
$2.893B |
|
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments: Proprietary Products and Contract-Manufactured Products.
|
